Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

GNbAC1

Monthly IV repeated dose

DRUG

Placebo

Monthly IV repeated dose

Trial Locations (12)

Unknown

Sofia

Zagreb

Jihlava

Tallinn

Berlin

Budapest

Roma

Warsaw

Moscow

Belgrade

Barcelona

Kharkiv

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Les Laboratoires Servier (LLS)

UNKNOWN

collaborator

Institut de Recherches Internationales Servier

OTHER

collaborator

Worldwide Clinical Trials

OTHER

lead

GeNeuro SA

INDUSTRY